BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34115644)

  • 1. Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination.
    Nduati EW; Gorman MJ; Sein Y; Hermanus T; Yuan D; Oyaro I; Muema DM; Ndung'u T; Alter G; Moore PL
    AIDS; 2021 Oct; 35(12):1895-1905. PubMed ID: 34115644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
    Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
    J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
    Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
    Front Immunol; 2021; 12():733958. PubMed ID: 34566999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.
    Richardson SI; Chung AW; Natarajan H; Mabvakure B; Mkhize NN; Garrett N; Abdool Karim S; Moore PL; Ackerman ME; Alter G; Morris L
    PLoS Pathog; 2018 Apr; 14(4):e1006987. PubMed ID: 29630668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
    Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
    Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.
    Motsoeneng BM; Manamela NP; Kaldine H; Kgagudi P; Hermanus T; Ayres F; Makhado Z; Moyo-Gwete T; van der Mescht MA; Abdullah F; Boswell MT; Ueckermann V; Rossouw TM; Madhi SA; Moore PL; Richardson SI
    Front Immunol; 2023; 14():1231276. PubMed ID: 37600825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions.
    Schriek AI; van Haaren MM; Poniman M; Dekkers G; Bentlage AEH; Grobben M; Vidarsson G; Sanders RW; Verrips T; Geijtenbeek TBH; Heukers R; Kootstra NA; de Taeye SW; van Gils MJ
    Front Immunol; 2022; 13():893648. PubMed ID: 35651621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond Viral Neutralization.
    Lewis GK; Pazgier M; Evans DT; Ferrari G; Bournazos S; Parsons MS; Bernard NF; Finzi A
    AIDS Res Hum Retroviruses; 2017 Aug; 33(8):760-764. PubMed ID: 28084796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection.
    Muenchhoff M; Chung AW; Roider J; Dugast AS; Richardson S; Kløverpris H; Leslie A; Ndung'u T; Moore P; Alter G; Goulder PJR
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33361123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children.
    Kumar S; Batra H; Singh S; Chawla H; Singh R; Katpara S; Hussain AW; Das BK; Lodha R; Kabra SK; Luthra K
    J Gen Virol; 2020 Dec; 101(12):1289-1299. PubMed ID: 32915123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
    Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
    J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women.
    Fisher KL; Mabuka JM; Sivro A; Ngcapu S; Passmore JS; Osman F; Ndlovu B; Abdool Karim Q; Abdool Karim SS; Chung AW; Baxter C; Archary D
    Front Immunol; 2020; 11():1274. PubMed ID: 32733445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.
    Chung AW; Mabuka JM; Ndlovu B; Licht A; Robinson H; Ramlakhan Y; Ghebremichael M; Reddy T; Goulder PJR; Walker BD; Ndung'u T; Alter G
    AIDS; 2018 Jun; 32(10):1207-1217. PubMed ID: 29620716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus.
    Lucier A; Fong Y; Li SH; Dennis M; Eudailey J; Nelson A; Saunders K; Cunningham CK; McFarland E; McKinney R; Moody MA; LaBranche C; Montefiori D; Permar SR; Fouda GG
    J Infect Dis; 2022 May; 225(10):1731-1740. PubMed ID: 34962990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
    Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
    EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza Vaccination Results in Differential Hemagglutinin Stalk-Specific Fc-Mediated Functions in Individuals Living With or Without HIV.
    Motsoeneng BM; Dhar N; Nunes MC; Krammer F; Madhi SA; Moore PL; Richardson SI
    Front Immunol; 2022; 13():873191. PubMed ID: 35514992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
    Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA
    Front Immunol; 2018; 9():3163. PubMed ID: 30697215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
    Brady T; Cayatte C; Roe TL; Speer SD; Ji H; Machiesky L; Zhang T; Wilkins D; Tuffy KM; Kelly EJ
    Front Immunol; 2023; 14():1283120. PubMed ID: 37901217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis.
    Phelps M; Balazs AB
    Front Immunol; 2021; 12():734304. PubMed ID: 34603314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.